Cobra Biologics
http://www.cobrabio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cobra Biologics
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Scancell Soars On 'Universal' COVID-19 Vaccine Claims
The current coronavirus vaccines focus on the spike protein but the UK's Scancell believes it has a candidate that also targets the SARS-CoV-2 nucleocapsid protein which could help tackle existing and future variants.
Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Company Information
- Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
- Other Names / Subsidiaries
-
- Cognate BioServices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice